Skip to content
NewsBlazeIN – Lifestyle
Author:
Galimedix Therapeutics, Inc.
Galimedix Therapeutics to present functional feasibility data from Phase 2 eDREAM study in geographic atrophy at 26th EURETINA Congress
September 11, 2026
Galimedix Therapeutics presents strong pharmacokinetic profile of next-generation oral Alzheimer’s candidate at AD/PD™ 2026
March 20, 2026
Galimedix Therapeutics earns milestone payment in ophthalmology partnership with Théa Open Innovation
March 12, 2026